Neuralstem, Inc has received notice of allowance from the United States Patent and Trademark Office (US PTO) for its patent entitled 'Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions', number 11/281,640.
"We are gratified to add this important core technology patent to our portfolio," said Neuralstem president & CEO Richard Garr. "The transplantation of our neural stem cells to treat degenerative conditions of the nervous system is at the heart of Neuralstem's mission."
"Most importantly," said Neuralstem chief scientific officer, Dr Karl Johe, "The claims in this patent cover the manufacturing process of our future products from all regions of the human central nervous system (brain and spinal cord) through July of 2026."
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.